

Special Issue

Role of Factors in Embryo Implantation and Placental Development

Message from the Guest Editors

Implantation is a crucial event and a major limiting step a successful pregnancy. Proper embryo–endometrium crosstalk occurs, governed by factors and molecular pathways, and the dysregulation of one or more signals of this complex network may cause implantation failure and recurrent pregnancy loss, which may lead to infertility. The present Special Issue, edited by and , aims to better clarify and unravel novel factors and molecular pathways regulating blastocyst–endometrium crosstalk and placental development, whose dysregulation might be associated with infertility and pregnancy disorders, and the most recent therapeutic approaches to treat these pathologies.

This Special Issue is now open for submissions. Prospective authors should first send a short abstract or tentative title to the Editorial Office. If the editors deem the topic to be appropriate for inclusion in this Special Issue, the author will be encouraged to submit a full manuscript.

Guest Editors

Dr. Micol Massimiani

BIO/17 Histology, Saint Camillus International University of Health and Medical Sciences, 00131 Roma, Italy

Dr. Valentina Lacconi

1. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

2. Saint Camillus International, University of Health Sciences, Rome, Italy

Deadline for manuscript submissions

closed (31 December 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/187472

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).